13 results about "Brain ischemia" patented technology

The application discloses a kind of mouse brain ischemic lesion automatic quantification method and system based on deep learning, belong to medical image processing and artificial intelligence technical field.The method includes: standardization pretreatment is carried out to T1WI, T2WI, DTI and ASL and other multi-modal MRI data, and enhanced feature tensor is constructed;Lesion intelligent preliminary segmentation is carried out using BA-U-Net network guided by physical prior, and biophysical consistency loss is introduced;Boundary refining is carried out to segmentation result using graph convolution network;Based on LDDMM registration and neural ordinary differential equation model, dynamic evolution modeling is carried out to multi-time point lesion, and severity score is calculated;Finally, comprehensive pathophysiological feature vector is constructed, XGBoost model is used for prediction, and interactive report containing 3D visual model is generated by SHAP explanation.The system includes corresponding functional module.The application realizes high-precision, reproducible automatic quantification to fuzzy lesion, improves the robustness of pathological pattern recognition, and provides dynamic biomarker for drug evaluation.

A system for the real-time detection of cerebral ischemic events using multichannel near-infrared spectroscopy, comprising: a head-attachable structural assembly made of a flexible or semi-rigid biocompatible substrate configured to conform to the skull surface of a subject; a plurality of near-infrared light-emitting units embedded in the structure and arranged in a spatially distributed configuration over predefined areas corresponding to brain regions; a plurality of photodetector units arranged at predetermined distances from the respective light-emitting units to define a plurality of measurement channels, each measurement channel configured to receive diffusely reflected near-infrared light from the underlying brain tissue;a signal acquisition unit electrically coupled to the photodetector units and configured to convert received optical signals into corresponding electrical signals, and additionally amplifying, filtering, and digitizing them; a processing unit operationally coupled to the signal acquisition unit and configured to calculate fluctuations in cerebral oxygenation based on the digitized signals and to identify patterns indicative of cerebral ischemic events in real time; and a communication unit configured to transmit processed data and event notifications to an external system.

The invention discloses low-temperature injectable hydrogel as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. Hydrogel is prepared from high-molecular-weight hyaluronic acid grafted with vitamin E and poly (N-isopropylacrylamide), the hydrogel is in an injectable liquid state at 4 DEG C, and a drug capsaicin (CPZ) wrapped by micelle is loaded and injected into the brain from the brain in a stereotactic mode. The pharmaceutical composition can temporarily maintain local low temperature of brain tissue and release capsaicin, reduce local metabolic activity of ischemic brain tissue, temporarily inhibit biogenesis, reduce NADH, FADH2 and other reducing equivalents and ADP accumulation, reduce the possibility of electron leakage in an electron transport chain, and improve the bioavailability of ischemic brain tissue. Vitamin E is added to reduce superoxide anions (O2 <.->) generated by reduction reaction of oxygen and leaked electrons in the reperfusion process, and vitamin E can promote ROS removal, synergistically alleviate oxidative stress and subsequent inflammation, and comprehensively improve cerebral ischemia reperfusion injury.

This invention discloses a brain-targeting neutrophil membrane-encapsulated tanshinone IIa PLGA nanoparticle formulation, its preparation method, and its uses. The brain-targeting tanshinone IIa nanoparticle formulation, Neu-Tan-IIa@PLGA, is characterized by comprising a PLGA-loaded tanshinone IIa nanoparticle core (Tan-IIa@PLGA) and an outer neutrophil membrane coating. This invention effectively overcomes the problems of poor water solubility, low oral bioavailability, and difficulty in crossing the blood-brain barrier associated with tanshinone IIa. This invention provides a tanshinone IIa with strong targeting and high drug stability, enabling delivery to lesions in ischemic brain regions and improving the safety and efficacy of stroke treatment.

The invention discloses a tongue exercise and respiration collaborative conditioning method for improving refractory insomnia, and relates to the field of human health conditioning and sleep medicines.The method comprises the steps that tongue exercise exercise of a preset duration is executed in the period before sleep every day, abdominal or inverse abdominal respiration regulation is conducted in a synchronous and matched mode, and therefore tongue muscle groups are activated. In the morning or before afternoon every day, a skin needle therapy (oblique puncturing for 0.5 mm) and a bloodletting therapy are performed on specific acupuncture points (such as Yingwei points) in the oral cavity so as to activate and disperse blood stasis and increase qi and blood flow. Through the synergistic effect of lingual exercise, breathing conditioning and skin needle / bloodletting therapy, the blood supply state of the brain and the heart is improved, so that the intractable insomnia symptom caused by neurasthenia, physical weakness, cardio-cerebral ischemia and the like is relieved from the source. The method emphasizes multi-dimensional collaborative conditioning, can adapt to different crowds, can be dynamically adjusted through effect evaluation, and aims to realize a physical insomnia intervention mode without drug dependence.

The application discloses a 4-(benzo[d]thiazol-2-yl)benzene-1,2-ethylenediamine compound and a preparation method and application thereof. The structural formula of the compound is: the compound has strong ROS scavenging capacity, inhibits lipid peroxidation, can inhibit ferroptosis caused by an iron death inducer, can reduce brain ischemia and nerve damage caused by brain ischemia, and can relieve symptoms of Parkinson's syndrome and other neurological diseases. Therefore, the ferroptosis inhibitor based on the ferrostain-1 / lirilad structure provided by the application can treat diseases related to ferroptosis through multiple actions and has the potential to be developed into a drug for treating diseases related to ferroptosis. Moreover, the ferroptosis inhibitor can be used as an antioxidant fluorescent probe for high-sensitivity detection of a ferroptosis marker, lipid peroxide (PCOOH / PEOOH), can effectively reverse the ferroptosis process of cells, and has a self-indication capacity. The ferroptosis inhibitor is a solid powder, is convenient to store and use, has a simple synthesis method, high yield, low cost, and good popularization prospect.

The application belongs to the technical field of biological medicine, and particularly relates to a beta-carboline quinoline azo oxonium based on hypoxia response and a preparation method and application thereof. The application constructs a brain ischemia activated beta-carboline quinoline azo oxonium shown in the following formula. The beta-carboline quinoline azo oxonium realizes focal specific release of NO through reduction and fracture of an azo bond, and can integrate near-infrared fluorescence imaging function to provide real-time visual monitoring for treatment response.

Compounds described herein may be used for the treatment of neurodegenerative diseases linked to protein misfolding, including prion diseases, Alzheimer's disease, Parkinson's disease (PD) and amyotrophic lateral sclerosis (ALS), and also other neurodegenerative, degenerative, metabolic and ischemic conditions. Indeed, NAD metabolism impairment is also a critical feature in brain ischemia / reperfusion injury, Wallerian degeneration, kidney failure, multiple sclerosis, aging, and metabolic disorders such as diabetes mellitus. Therapies that elevate or stabilize NAD levels may thus have broad potential for treating many severely debilitating neurological and metabolic conditions. Evidence is provided herein with compounds from 8 lead series for NAD restoring properties and for therapeutic efficacy in cellular and / or animal models of prion disease, PD and ALS.

This invention provides a drug delivery system and its application based on brain microvascular endothelial cells, comprising stimulated brain microvascular endothelial cells, wherein the stimulation is performed by culturing in a culture system containing supernatant of brain microvascular endothelial cells cultured under glucose and oxygen deprivation. This invention solves the problems of targeting and timeliness in treating blood-brain barrier damage after ischemic stroke under current technologies. It can regulate the BBB while supporting its function and structure, maintaining and repairing BBB function after reperfusion, thus improving the prognosis of stroke treatment. The cell preparations in this invention are widely available and easily obtained, and can rapidly repair the blood-brain barrier. Furthermore, the cell preparations in this invention can target ischemic brain sites and can be administered via simple intravenous injection, facilitating clinical operation.

The invention discloses an oxygen storage and aeration method for a toilet, and aims to prevent accidental injury of old people caused by oxygen deficit. According to the scheme, the device is composed of an outdoor oxygen generator, an indoor oxygen storage system and a control system, the indoor oxygen storage system comprises an oxygen gathering box and an oxygen storage bag, and the oxygen storage bag is connected with the oxygen gathering box through an air pipe connector; one end of the oxygen gathering box is connected to the outdoor oxygen generator, and the other end is connected to the fan; an electromagnetic valve is arranged between the oxygen gathering box and the fan, and an electromagnetic valve is also arranged between the outdoor oxygen generator and the oxygen gathering box; the indoor oxygen storage system is mounted on a ceiling of a bathroom. During bathing, the corresponding electromagnetic valves and the corresponding fans are turned on, the stored oxygen is rapidly pumped out, the oxygen content of a toilet is increased, the effects of ischemia and hypoxia of the brain are offset, and the effect of preventing dizziness and falling down is achieved.

The application discloses a kind of functionalization exosome-traditional Chinese medicine small molecule composite preparation T-pEXOs@GB and its preparation method and application.The composite preparation encapsulates ginkgolide B (GB) in the exosome of healthy plasma, and is functionally modified neuron target peptide RVG (DSPE-PEG-RVG) on its surface, so that it has brain targeting and oxygen supply functions.The preparation method provided by the application can efficiently and controllably prepare the composite preparation with uniform particle size and good stability.The T-pEXOs@GB composite preparation of the application can be targeted to deliver to brain ischemia and hypoxia injury area, significantly reduce oxidative stress and inflammatory response, reduce cerebral infarction volume, improve neurological deficit score, and improve the survival rate of animal model, and can be used to prepare drugs for preventing and treating acute high altitude cerebral hypoxia, ischemic stroke, neonatal hypoxic-ischemic encephalopathy and other cerebral ischemia and hypoxia injury, and has good market prospect.

This invention relates to the application of compound ID-8 in the preparation of drugs for treating ischemic cerebrovascular diseases. This invention demonstrates the protective effect of ID-8 on ischemic brain. Research data shows that ID-8 can significantly reduce brain tissue damage and cell death caused by ischemic stroke, shrink infarct foci, and improve neurological function. Compound ID-8 can be used to prepare drugs for treating ischemic cerebrovascular diseases, can be combined with various excipients, can be combined with various existing drugs for treating ischemic cerebrovascular diseases, and is applicable to various dosage forms and routes of administration. This results in novel, safe, and effective drugs and treatments for ischemic cerebrovascular diseases that can reduce brain ischemia-related damage, and has significant clinical and social value.

The present application provides a temperature-sensitive hydrogel system for intranasal delivery of mesenchymal stem cells and application, which comprises a poloxamer hydrogel as a carrier and mesenchymal stem cells loaded on the carrier; the poloxamer hydrogel as a carrier comprises poloxamer 407 and poloxamer 188, and further comprises at least one of epidermal growth factor and fibroblast growth factor. The present application solves the problems of low efficiency of mesenchymal stem cells into the brain and poor survival ability of mesenchymal stem cells in the nasal cavity in the treatment of ischemic stroke under the current technology, improves the accumulation and activity of mesenchymal stem cells in the lesion site, and improves the prognosis of stroke treatment. The cell preparation in the present application can target the brain ischemic site, and can be administered by non-invasive intranasal administration, avoiding the risk of secondary trauma caused by invasive administration.